CA2462632A1 - Introduction du gene wlds pour la prevention de la degenerescence axonale dans les maladies neurologiques - Google Patents

Introduction du gene wlds pour la prevention de la degenerescence axonale dans les maladies neurologiques Download PDF

Info

Publication number
CA2462632A1
CA2462632A1 CA002462632A CA2462632A CA2462632A1 CA 2462632 A1 CA2462632 A1 CA 2462632A1 CA 002462632 A CA002462632 A CA 002462632A CA 2462632 A CA2462632 A CA 2462632A CA 2462632 A1 CA2462632 A1 CA 2462632A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
wlds
polynucleotide sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002462632A
Other languages
English (en)
Inventor
Jonathan D. Glass
Mark M. Rich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2462632A1 publication Critical patent/CA2462632A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des polypeptides qui peuvent protéger les axones de la dégénérescence, ainsi que des méthodes d'utilisation de ces polypeptides. Elle concerne aussi des polynucléotides qui peuvent protéger les axones de la dégénérescence, ainsi que des méthodes d'utilisation de ces polynucléotides. Elle concerne encore des polynucléotides codant pour les polypeptides de l'invention. Elle concerne enfin des compositions pharmaceutiques destinées à traiter ces troubles.
CA002462632A 2001-10-01 2002-10-01 Introduction du gene wlds pour la prevention de la degenerescence axonale dans les maladies neurologiques Abandoned CA2462632A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32635401P 2001-10-01 2001-10-01
US60/326,354 2001-10-01
PCT/US2002/031078 WO2003029414A2 (fr) 2001-10-01 2002-10-01 Introduction du gene wlds pour la prevention de la degenerescence axonale dans les maladies neurologiques

Publications (1)

Publication Number Publication Date
CA2462632A1 true CA2462632A1 (fr) 2003-04-10

Family

ID=23271854

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002462632A Abandoned CA2462632A1 (fr) 2001-10-01 2002-10-01 Introduction du gene wlds pour la prevention de la degenerescence axonale dans les maladies neurologiques

Country Status (3)

Country Link
EP (1) EP1446014A4 (fr)
CA (1) CA2462632A1 (fr)
WO (1) WO2003029414A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429560B2 (en) * 2002-09-25 2008-09-30 Georgia Tech Research Corporation Ketoamide inhibitors in chronic nerve disease
GB201006961D0 (en) * 2010-04-27 2010-06-09 Babraham Inst NMN modulator
EP3648776A4 (fr) * 2017-07-06 2021-04-07 The Medical College of Wisconsin, Inc. Nouvelle stratégie d'enrichissement in vitro et in vivo ciblant les lymphocytes dérivés de csh transduites par un vecteur pour la thérapie de troubles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525048A (ja) * 2000-03-02 2003-08-26 インサイト・ゲノミックス・インコーポレイテッド 脂質代謝酵素

Also Published As

Publication number Publication date
EP1446014A4 (fr) 2004-12-08
EP1446014A2 (fr) 2004-08-18
WO2003029414A2 (fr) 2003-04-10
WO2003029414A3 (fr) 2003-12-18

Similar Documents

Publication Publication Date Title
JP5822897B2 (ja) 血管新生及び脈管形成のモジュレーターとしてのｒスポンジン
US7777005B2 (en) Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
JP2008194039A (ja) 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法
US6555667B1 (en) Hypoxia-regulated genes
US20060127397A1 (en) RAG polypeptides, nucleic acids, and their use
KR100640265B1 (ko) Ｌｙ6ｈ 유전자
AU760466B2 (en) A novel inhibitor of programmed cell death
US20030175260A1 (en) Novel DNA and a process for its use
EP1163252A2 (fr) Compositions, kits et procedes concernant le gene fez1 de l'homme, nouveau gene suppresseur des tumeurs
CA2462632A1 (fr) Introduction du gene wlds pour la prevention de la degenerescence axonale dans les maladies neurologiques
SK121798A3 (en) Native protein of a complement line, a fragment or variant of protein, dna sequence coding a protein, dna construct, a conjugate containing protein, pharmaceutical composition and use of protein
US20040127439A1 (en) Introduction of the wld gene for prevention of axonal degeneration in neurological diseases
AU2002362458A1 (en) Introduction of the WLDs gene for prevention of axonal degeneration in neurological diseases
JPH11253183A (ja) Ｆｒｉｚｚｌｅｄ−３ポリペプチドおよびポリヌクレオチド
AU2001264245B2 (en) Novel enzyme gene and its expression product
US7160722B2 (en) Master bone formation transcription factor: compositions and methods of use
US20110130335A1 (en) Therapeutic agent and test agent for disease with myocardial necrosis
US6503502B1 (en) Nucleotide sequences, proteins, drugs and diagnostic agents of use in treating cancer
JP4112976B2 (ja) Ｐｃａ２５０１遺伝子
JP4582896B2 (ja) Ｋ１遺伝子
EP1434598A2 (fr) Proteines de bestrophine et homologues de bestrophine impliquees dans la regulation de l'homeostasie de l'energie
JP4147058B2 (ja) 精神分裂病診断剤
US6291173B1 (en) MMSC2—an MMAC1 interacting protein
JP2008118989A (ja) Ｐｃａ２５０１遺伝子
EP1390483A2 (fr) Gene codant une nouvelle proteine de type moteur moleculaire et procede diagnostique pour une maladie liee a ce gene

Legal Events

Date Code Title Description
FZDE Dead